1 Newborn Screening; Globoid Cell Leukodystrophy (Krabbe). Amend the introductory paragraph of RSA 132:10-a, I to read as follows:

I. The physician, hospital, nurse midwife, midwife, or other health care provider attending a newborn child shall test a newborn child for metabolic disorders. Such tests shall include, but not be limited to, phenylketonuria, galactosemia, homocystinuria, maple syrup urine disease, and hypothyroidism, and globoid cell leukodystrophy (krabbe). Additional disorders shall be added to the newborn screening panel based upon, but not limited to, the following considerations:

2 Effective Date. This act shall take effect 60 days after its passage.

1 Newborn Screening; Globoid Cell Leukodystrophy (Krabbe). Amend the introductory paragraph of RSA 132:10-a, I to read as follows:

I. The physician, hospital, nurse midwife, midwife, or other health care provider attending a newborn child shall test a newborn child for metabolic disorders. Such tests shall include, but not be limited to, phenylketonuria, galactosemia, homocystinuria, maple syrup urine disease, hypothyroidism, and globoid cell leukodystrophy (krabbe). Additional disorders shall be added to the newborn screening panel based upon, but not limited to, the following considerations:

2 Effective Date. This act shall take effect 60 days after its passage.